Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.
|NCT04781088||II||Platinum resistant ovarian cancer||Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer||OH, PA||View Drugs||View Results |
|Paclitaxel||Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL||Microtubule stabilizer/mitotic inhibitor||Approved in Ovarian Cancer|
|Lenvatinib||MK-7902, Lenvima, ER-203492-00, E7080||Multi-targeted RTK inhibitor||Approved in Other Cancers|
|Pembrolizumab||Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475||Blocks PD-L1/2 inhibition of T cells||Approved in Other Cancers|